Nektar Therapeutics' GAAP loss for 2020 was $444.44 million, up 0.9% from $440.667 million in the prior year. Revenue increased 33.4% to $152.915 million from $114.617 million a year earlier.
Nektar Therapeutics' GAAP loss for 2020 was $444.44 million, up 0.9% from $440.667 million in the prior year. Revenue increased 33.4% to $152.915 million from $114.617 million a year earlier. 
ir.nektar.com
English (US) 